Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
作者： T. Forst , R. Guthrie , R. Goldenberg , J. Yee , U. Vijapurkar
DOI: 10.1111/DOM.12273
关键词: Type 2 Diabetes Mellitus 、 Urology 、 Canagliflozin 、 Type 2 diabetes 、 Metformin 、 Pioglitazone 、 Blood pressure 、 SGLT2 Inhibitor 、 Pharmacology 、 Weight loss 、 Medicine
摘要: Aim The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated in patients with type diabetes mellitus (T2DM) inadequately controlled metformin pioglitazone.
researchgate.net 
sci-hub.se 参考文章(29)
L. Chen, T. Klein, P. S. Leung, Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice Current Molecular Medicine. ,vol. 12, pp. 995- 1004 ,(2012) , 10.2174/156652412802480970
Richard M Bergenstal, Carol Wysham, Leigh MacConell, Jaret Malloy, Brandon Walsh, Ping Yan, Ken Wilhelm, Jim Malone, Lisa E Porter, None, Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial The Lancet. ,vol. 376, pp. 431- 439 ,(2010) , 10.1016/S0140-6736(10)60590-9
S. E. Inzucchi, R. M. Bergenstal, J. B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. L. Peters, A. Tsapas, R. Wender, D. R. Matthews, Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia. ,vol. 55, pp. 1577- 1596 ,(2012) , 10.1007/S00125-012-2534-0
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Peter Stein, Mehul Desai, Wayne Shaw, Joel Jiang, Frank Vercruysse, Gary Meininger, David Matthews, None, Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial American Heart Journal. ,vol. 166, pp. 217- 223.e11 ,(2013) , 10.1016/J.AHJ.2013.05.007
A. J. Scheen, M. H. Tan, D. J. Betteridge, K. Birkeland, O. Schmitz, B. Charbonnel, , Long‐term glycaemic effects of pioglitazone compared with placebo as add‐on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18) Diabetic Medicine. ,vol. 26, pp. 1242- 1249 ,(2009) , 10.1111/J.1464-5491.2009.02857.X
Bruce Bode, Kaj Stenlöf, Daniel Sullivan, Albert Fung, Keith Usiskin, Efficacy and Safety of Canagliflozin Treatment in Older Subjects With Type 2 Diabetes Mellitus: A Randomized Trial Hospital Practice. ,vol. 41, pp. 72- 84 ,(2013) , 10.3810/HP.2013.04.1020
J. Rosenstock, M. Vico, L. Wei, A. Salsali, J. F. List, Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy Diabetes Care. ,vol. 35, pp. 1473- 1478 ,(2012) , 10.2337/DC11-1693
G. Bolli, F. Dotta, L. Colin, B. Minic, M. Goodman, Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes, Obesity and Metabolism. ,vol. 11, pp. 589- 595 ,(2009) , 10.1111/J.1463-1326.2008.01023.X
William T Cefalu, Lawrence A Leiter, Kun-Ho Yoon, Pablo Arias, Leo Niskanen, John Xie, Dainius A Balis, William Canovatchel, Gary Meininger, Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial The Lancet. ,vol. 382, pp. 941- 950 ,(2013) , 10.1016/S0140-6736(13)60683-2
David Polidori, Sue Sha, Atalanta Ghosh, Leona Plum-Mörschel, Tim Heise, Paul Rothenberg, Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus The Journal of Clinical Endocrinology and Metabolism. ,vol. 98, ,(2013) , 10.1210/JC.2012-4205